Oslo, 5 February 2026: On the basis of the authorization granted by the General Meeting on 29 April 2025 for the Board of Directors of Zelluna ASA (the “Company”, OSE ticker “ZLNA”) to issue shares to employees and board members under a long-term incentive program, the Board of Directors has resolved to grant share options to two employees in the Company.
Oslo, Norway, 20 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, announces its second quarter 2025 results today.
Oslo, Norway, 14 August 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites you to a webcast presentation of its second quarter 2025 results, on Wednesday, August 20, 2025.
